BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 28316374)

  • 1. The Role of IL-17 and Related Cytokines in Inflammatory Autoimmune Diseases.
    Kuwabara T; Ishikawa F; Kondo M; Kakiuchi T
    Mediators Inflamm; 2017; 2017():3908061. PubMed ID: 28316374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The roles of IL-17A in inflammatory immune responses and host defense against pathogens.
    Iwakura Y; Nakae S; Saijo S; Ishigame H
    Immunol Rev; 2008 Dec; 226():57-79. PubMed ID: 19161416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases.
    Yamagata T; Skepner J; Yang J
    Arch Immunol Ther Exp (Warsz); 2015 Dec; 63(6):405-14. PubMed ID: 26358867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
    Roeleveld DM; van Nieuwenhuijze AE; van den Berg WB; Koenders MI
    BioDrugs; 2013 Oct; 27(5):439-52. PubMed ID: 23620106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential.
    Zhu S; Qian Y
    Clin Sci (Lond); 2012 Jun; 122(11):487-511. PubMed ID: 22324470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis.
    Hirota K; Hashimoto M; Yoshitomi H; Tanaka S; Nomura T; Yamaguchi T; Iwakura Y; Sakaguchi N; Sakaguchi S
    J Exp Med; 2007 Jan; 204(1):41-7. PubMed ID: 17227914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited.
    Boniface K; Blom B; Liu YJ; de Waal Malefyt R
    Immunol Rev; 2008 Dec; 226():132-46. PubMed ID: 19161421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diseases that may benefit from manipulating the Th17 pathway.
    Miossec P
    Eur J Immunol; 2009 Mar; 39(3):667-9. PubMed ID: 19283719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th17 cytokines and their emerging roles in inflammation and autoimmunity.
    Fouser LA; Wright JF; Dunussi-Joannopoulos K; Collins M
    Immunol Rev; 2008 Dec; 226():87-102. PubMed ID: 19161418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innately versatile: γδ17 T cells in inflammatory and autoimmune diseases.
    Papotto PH; Reinhardt A; Prinz I; Silva-Santos B
    J Autoimmun; 2018 Feb; 87():26-37. PubMed ID: 29203226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-17-producing T cells in lung immunity and inflammation.
    Nembrini C; Marsland BJ; Kopf M
    J Allergy Clin Immunol; 2009 May; 123(5):986-94; quiz 995-6. PubMed ID: 19410688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases.
    Qu N; Xu M; Mizoguchi I; Furusawa J; Kaneko K; Watanabe K; Mizuguchi J; Itoh M; Kawakami Y; Yoshimoto T
    Clin Dev Immunol; 2013; 2013():968549. PubMed ID: 23956763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17 as a drug target in human disease.
    Ivanov S; Lindén A
    Trends Pharmacol Sci; 2009 Feb; 30(2):95-103. PubMed ID: 19162337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12 family members and type I interferons in Th17-mediated inflammatory disorders.
    Goriely S; Cavoy R; Goldman M
    Allergy; 2009 May; 64(5):702-9. PubMed ID: 19383026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Th17 cells in autoimmune diseases.
    Yang J; Sundrud MS; Skepner J; Yamagata T
    Trends Pharmacol Sci; 2014 Oct; 35(10):493-500. PubMed ID: 25131183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathogenicity of Th17 cells in autoimmune diseases.
    Yasuda K; Takeuchi Y; Hirota K
    Semin Immunopathol; 2019 May; 41(3):283-297. PubMed ID: 30891627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-37 Alleviates Rheumatoid Arthritis by Suppressing IL-17 and IL-17-Triggering Cytokine Production and Limiting Th17 Cell Proliferation.
    Ye L; Jiang B; Deng J; Du J; Xiong W; Guan Y; Wen Z; Huang K; Huang Z
    J Immunol; 2015 Jun; 194(11):5110-9. PubMed ID: 25917106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis.
    Astry B; Harberts E; Moudgil KD
    J Interferon Cytokine Res; 2011 Dec; 31(12):927-40. PubMed ID: 22149412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of interleukin-17A in psoriatic disease.
    Adami S; Cavani A; Rossi F; Girolomoni G
    BioDrugs; 2014 Dec; 28(6):487-97. PubMed ID: 24890029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.